SimBioSys

About SimBioSys

SimBioSys is a technology company leveraging artificial intelligence and biophysical modeling to enhance precision medicine in oncology. The company was founded in 2018 by Dr. Joseph Peterson, Dr. John Cole, and Tushar Pandey, originating from research conducted at the University of Illinois Urbana-Champaign. Pandey, who initially served as CEO, was motivated by his mother's cancer diagnosis and his research into healthcare cost reduction. Dr. Peterson, a graduate of the Illinois Chemistry Department, has a background in developing software for scientific discovery, while Dr. Cole is the Chief Scientific Officer. In early 2025, Stacey Stevens, with prior experience at iCAD and Philips Healthcare, was appointed President and CEO to guide the company's commercial growth.

SimBioSys's core technology, the TumorScope™ platform, creates a 3D digital twin of a patient's tumor using standard diagnostic data like MRI scans. This virtual model integrates AI with biophysical simulations to model variables such as drug delivery, metabolism, and spatial heterogeneity, predicting how a tumor will respond to various therapies. The platform aims to provide clinicians with insights to personalize treatment plans, assess all available options computationally, and improve patient outcomes. The company's initial focus is on breast cancer, with plans to expand to other solid tumors like lung and prostate cancer. One of its key products, TumorSight™ Viz, is an FDA-cleared cloud-based tool that assists surgeons in preoperative planning by converting 2D MRI studies into interactive 3D models.

The company operates on a B2B model, generating revenue through subscription-based access and partnerships with healthcare institutions, cancer centers, and biopharmaceutical companies. Its technology is used for clinical decision-making, patient education, and to support drug development in preclinical and clinical trials. SimBioSys has established collaborations with over 20 cancer institutions, including the Mayo Clinic and UT Southwestern Medical Center. The company has secured over $21 million in funding from investors such as Genoa Ventures, Northpond Ventures, and the Mayo Clinic.